Danaher Corporation (DHR - Free Report) stands to benefit from a strong performance of its Life Sciences segment owing to robust demand for bioprocessing products despite supply-chain constraints and raw material cost inflation.
High activity levels from early-stage research to later-stage development and production should aid the bioprocessing business. Healthy demand for products related to molecular testing and higher non-COVID testing volumes will be beneficial to the Diagnostics segment. Also, strength across DHR’s consumables business and solid demand for equipment are steadily driving its Environmental & Applied Solutions segment’s performance. Danaher expects core revenue growth in the range of low-single digits for the third quarter of 2022 and mid-single digits for 2022 from the respective year-ago period’s actuals.
DHR’s acquisition of Aldevron (August 2021) enhanced its foothold in the genomic medicine field. Also, Danaher added Vanrx Pharmasystems and Swift Biosciences to its portfolio in first-quarter 2021. In second-quarter 2022, acquisitions boosted DHR’s sales 2.5%.
Danaher’s policy of rewarding its shareholders handsomely through dividend payments and share buybacks is worth mentioning. DHR used $411 million to pay out dividends in the first six months of 2022. The quarterly dividend rate was hiked 4 cents in February 2022.
In light of the above-mentioned positives, we believe, investors should hold on to the Danaher stock for now, as is suggested by its current Zacks Rank #3 (Hold).
In the past six months, the stock has inched up 2% against the industry’s decline of 3.9%.
Stocks to Consider
Some better-ranked companies are discussed below.
Carlisle Companies (CSL - Free Report) sports a Zacks Rank #1 (Strong Buy), currently. CSL pulled off a trailing four-quarter earnings surprise of 28%, on average. You can see the complete list of today’s Zacks #1 Rank stocks.
In the past 60 days, Carlisle’s earnings estimates have increased 14.6% for 2022. The stock has rallied 28.8% in the past six months.
Griffon Corporation (GFF - Free Report) has a Zacks Rank #2 (Buy). GFF delivered a trailing four-quarter earnings surprise of 104.6%, on average.
In the past 60 days, Griffon’s earnings estimates have increased 3% for fiscal 2022 (ending September 2022). The stock has soared 47% in the past six months.
Valmont Industries, Inc. (VMI - Free Report) presently has a Zacks Rank of 2. VMI’s earnings surprise in the last four quarters was 13.7%, on average.
In the past 60 days, Valmont’s earnings estimates have increased 3.8% for 2022. The stock has rallied 31.3% in the past six months.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Danaher Corporation (DHR - Free Report) stands to benefit from a strong performance of its Life Sciences segment owing to robust demand for bioprocessing products despite supply-chain constraints and raw material cost inflation.
High activity levels from early-stage research to later-stage development and production should aid the bioprocessing business. Healthy demand for products related to molecular testing and higher non-COVID testing volumes will be beneficial to the Diagnostics segment. Also, strength across DHR’s consumables business and solid demand for equipment are steadily driving its Environmental & Applied Solutions segment’s performance. Danaher expects core revenue growth in the range of low-single digits for the third quarter of 2022 and mid-single digits for 2022 from the respective year-ago period’s actuals.
DHR’s acquisition of Aldevron (August 2021) enhanced its foothold in the genomic medicine field. Also, Danaher added Vanrx Pharmasystems and Swift Biosciences to its portfolio in first-quarter 2021. In second-quarter 2022, acquisitions boosted DHR’s sales 2.5%.
Danaher’s policy of rewarding its shareholders handsomely through dividend payments and share buybacks is worth mentioning. DHR used $411 million to pay out dividends in the first six months of 2022. The quarterly dividend rate was hiked 4 cents in February 2022.
In light of the above-mentioned positives, we believe, investors should hold on to the Danaher stock for now, as is suggested by its current Zacks Rank #3 (Hold).
In the past six months, the stock has inched up 2% against the industry’s decline of 3.9%.
Stocks to Consider
Some better-ranked companies are discussed below.
Carlisle Companies (CSL - Free Report) sports a Zacks Rank #1 (Strong Buy), currently. CSL pulled off a trailing four-quarter earnings surprise of 28%, on average. You can see the complete list of today’s Zacks #1 Rank stocks.
In the past 60 days, Carlisle’s earnings estimates have increased 14.6% for 2022. The stock has rallied 28.8% in the past six months.
Griffon Corporation (GFF - Free Report) has a Zacks Rank #2 (Buy). GFF delivered a trailing four-quarter earnings surprise of 104.6%, on average.
In the past 60 days, Griffon’s earnings estimates have increased 3% for fiscal 2022 (ending September 2022). The stock has soared 47% in the past six months.
Valmont Industries, Inc. (VMI - Free Report) presently has a Zacks Rank of 2. VMI’s earnings surprise in the last four quarters was 13.7%, on average.
In the past 60 days, Valmont’s earnings estimates have increased 3.8% for 2022. The stock has rallied 31.3% in the past six months.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VMI - FREE
Get the latest research report on DHR - FREE
Get the latest research report on CSL - FREE
Get the latest research report on GFF - FREE